Zentalis Pharmaceuticals Inc

ZNTL

$15.19

Closing

▲7.81%

1D

▲0.26%

YTD

Market cap

$1.08B

52 week high

$31.46

52 week low

$9.56

Volume

313,143

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$1.08B

Analysts' Rating

BUY

Price Target (Mean)

31.5

Total Analysts

10

P/E

Operating Margin

0.00%

Beta

1.72

Revenue Growth (Annual)

0.00%

52 week high

$31.46

52 week low

$9.56

Div. Yield

%

EPS Annual Growth

-57.30

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a focused pipeline of oncology candidates. The Company’s product candidates include Azenosertib (ZN-c3), a Wee1 inhibitor for advanced solid tumors and hematological malignancies; ZN-d5, a B-cell lymphoma 2 (BCL-2), inhibitor for hematological malignancies and related disorders; and a heterobifunctional degrader of BCL-xL, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. The Company is evaluating azenosertib and ZN-d5 in multiple ongoing clinical trials and conducting studies to enable an Investigational New Drug (IND), application for its BCL-xL product candidate. The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.